Literature DB >> 11164439

Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins.

J A Beentjes1, A van Tol, W J Sluiter, R P Dullaart.   

Abstract

Growth hormone (GH) deficiency and acromegaly may be associated with increased cardiovascular risk. Little is known about alterations in high density lipoproteins (HDL) in these conditions. Lecithin:cholesterol acyl transferase (LCAT) has the ability to esterify free cholesterol (FC) in HDL. Cholesteryl ester transfer protein (CETP) is able to transfer cholesteryl esters (CE) from HDL to very low and low density lipoproteins (VLDL and LDL). During phospholipid transfer protein (PLTP)-mediated HDL remodelling, small pre beta-HDL particles are generated which serve as acceptors for cellular cholesterol and provide the initial LCAT-substrate. We documented plasma lipids, LCAT, CETP and PLTP activity levels as well as plasma cholesterol esterification (EST) and cholesteryl ester transfer (CET) in 12 adult men with acquired GH deficiency, 12 acromegalic men and 24 healthy male subjects. All GH deficient and acromegalic patients received conventional hormonal replacement therapy if necessary. VLDL + LDL cholesterol and plasma triglycerides were higher in GH deficient (P < 0.01 and P < 0.05) and acromegalic patients (P < 0.05 and P < 0.01) than in healthy subjects. HDL cholesterol and HDL CE were lower (P < 0.05 for both) and the HDL FC/CE ratio was higher (P < 0.01) in these patient groups compared to healthy subjects. Plasma LCAT, CETP and PLTP activity levels were lower in acromegalic patients (P < 0.01 for all) and CETP activity was lower in GH deficient patients (P < 0.01) compared to healthy subjects. Plasma EST and CET were decreased in both acromegalic (P < 0.01 for both) and GH deficient patients (P < 0.05 for both). Multiple regression analysis demonstrated independent negative relationships of plasma insulin-like growth factor I with plasma LCAT (P = 0.0001), CETP (P = 0.009) and PLTP activity levels (P = 0.021). Plasma LCAT (P = 0.0001) and CETP activity (P = 0.0001) were also negatively associated with (substitution therapy for) adrenal insufficiency. In conclusion, GH deficient and acromegalic patients show abnormalities in HDL, consistent with impaired LCAT action. Decreases in plasma EST and CET in such patients, as well as a low PLTP activity in acromegaly suggest that reverse cholesterol transport may be impaired, contributing to increased cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11164439     DOI: 10.1016/s0021-9150(00)00433-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size.

Authors:  Hideo Makimura; Meghan N Feldpausch; Takara L Stanley; Noelle Sun; Steven K Grinspoon
Journal:  Clin Endocrinol (Oxf)       Date:  2012-02       Impact factor: 3.478

3.  Effects of Growth Hormone Treatment on Lipid Profiles.

Authors:  Toshihide Kubo; Mahoko Furujo; Kyohei Takahashi; Yuki Hyodo; Hiroki Tsuchiya; Mariko Hattori; Shoko Fujinaga; Kenji Urayama
Journal:  Indian J Pediatr       Date:  2017-11-11       Impact factor: 1.967

Review 4.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 5.  Management of Dyslipidemia in Endocrine Diseases.

Authors:  Lisa R Tannock
Journal:  Endocrinol Metab Clin North Am       Date:  2022-07-06       Impact factor: 4.748

6.  Comparison of biomarkers of oxidative stress and cardiovascular disease in humans and chimpanzees (Pan troglodytes).

Authors:  Elaine N Videan; Christopher B Heward; Kajal Chowdhury; John Plummer; Yali Su; Richard G Cutler
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

Review 7.  The Endothelium in Acromegaly.

Authors:  Pietro Maffei; Francesca Dassie; Alexandra Wennberg; Matteo Parolin; Roberto Vettor
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-24       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.